Drawing for Serial No. 88453131

USPTO serial 88453131

Serial No. 88453131

Reviewed by CopyMark Law Group

Reg. 6206673Status 702Renewal
Filing date
Status date
Registration date
Nov 24, 2020
Examiner
DIBLE, JONATHON I
Law office
Historical data usage

What this means

This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.

Status 702: Status 702 means the registration is active, Section 8 was accepted, and a Section 15 declaration of incontestability was also accepted. Incontestability strengthens your rights by limiting certain challenges after five years of continuous use.

Need help with Serial No. 88453131?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $399*

Plus Government fees of $325

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Douglas R. Wolf

Douglas R. Wolf WOLF, GREENFIELD & SACKS, P.C.600 ATLANTIC AVENUEBOSTON, MA 02210United States

Goods and services

ClassDescriptionStatusFirst use
005pharmaceutical preparations sold as a kit for use by pharmacists and physicians in creating compounded hormone replacement medicines, topical anti-inflammatory and ultrasound gels, pain and gastrointestinal disorders treatment medicines, and anti-inflammatory, antimicrobial, and antifungal treatment medicines; medicines for the treatment of cardiovascular diseases and disorders, colitis, muscle spasm, infectious diseases, acid-reflux disease, ulcer disease, and urological disorders; antibiotics; pharmaceutical products for the treatment of pain, thyroid disorders, gastrointestinal disorders, gastroesophageal disorders, inflammation, infections, fungal diseases and disorders, cardiovascular diseases and disorders, colitis, muscle spasm, attention deficit hyperactivity disorders, infectious diseases, acid-reflux disease, ulcer disease, and urological disorders having vancomycin, enalapril, lisinopril, and methotrexate as the active pharmaceutical ingredient; antacids; muscle relaxants; hormone replacement medicines; topical anti-inflammatory and ultrasound gels; pharmaceutical preparation for the treatment of pain, thyroid disorders, gastrointestinal disorders, gastroesophageal disorders, inflammation, infections, fungal diseases and disorders, cardiovascular diseases and disorders, colitis, muscle spasm, attention deficit hyperactivity disorders, infectious diseases, acid-reflux disease, ulcer disease, and urological disorders; pharmaceuticals for use in the treatment of cancer and autoimmune diseases and disorders, and for the treatment and prevention of renal, oncological, inflammatory, gastrointestinal, gastroesophageal, and cardio-vascular diseases and disordersACTIVEAug 31, 2020

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Sep 2, 2026NA85NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED—
Sep 2, 2026C15AREGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.—
Sep 1, 2026APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Jun 4, 2026E815TEAS SECTION 8 & 15 RECEIVED—
Nov 24, 2025REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Mar 19, 2025ASCKASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY—
Nov 24, 2020R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Oct 22, 2020SUNANOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED—
Oct 21, 2020CNPRALLOWED PRINCIPAL REGISTER - SOU ACCEPTED—
Oct 21, 2020SUPCSTATEMENT OF USE PROCESSING COMPLETE—
Oct 20, 2020AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Oct 6, 2020IUAFUSE AMENDMENT FILED—
Oct 6, 2020EISUTEAS STATEMENT OF USE RECEIVEDThe applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action.
Apr 29, 2020ASGNAUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP—
Apr 28, 2020NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Mar 3, 2020NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Mar 3, 2020PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Feb 12, 2020NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jan 30, 2020CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jan 29, 2020TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jan 29, 2020CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jan 29, 2020TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Aug 9, 2019GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 9, 2019GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 9, 2019CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 8, 2019DOCKASSIGNED TO EXAMINER—
Jun 15, 2019MDSCNOTICE OF DESIGN SEARCH CODE E-MAILED—
Jun 14, 2019NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jun 3, 2019NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance